OBJECTIVE: To evaluate the maximal secretory capacity of somatotrope cells in obesity and to compare it with that in hypopituitaric patients with GH de®ciency. DESIGN: Stimulation with GHRH. (1 mg/kg iv) combined with arginine (ARG, 0.5 g/kg iv), which strongly potentiates the GH response to the neurohormone, likely inhibiting hypothalamic somatostatin. The reproducibility of the GH response to GHRH ARG was evaluated in a second session. SUBJECTS: Forty-®ve patients with simple obesity (OB 11 male and 34 female, age 40.5 AE AE 1.8 y, BMI 38.8 AE AE 1.1 kg/m 2 ), 49 patients with hypopituitarism (GHD, 23 male and 26 female, 43.6 AE AE 2.4 y, 24.7 AE AE 0.7 kg/m 2 ) and 44 normal young volunteers (NS, 25 male and 19 female, 33.8 AE AE 1.0 y, 21.6 AE AE 0.3 kg/m 2 ) were studied. MEASUREMENTS: GH levels were assayed by IRMA method, basally at 7 60 and 0 min, and than every 15 min up to 120 min. Basal IGF±I levels were assayed by RIA method, after acid-ethanol extraction. RESULTS: IGF±I levels in OB were lower (P`0.005) than those in NS but higher (P`0.005) than those in GHD. Mean peak GH response to GHRH ARG in OB was clearly lower than that in NS (P`0.005) and higher (P`0.005) than that in GHD. Sixty±percent OB and 100% GHD showed peak GH responses lower than the minimum normal limit in NS (16.5 mg/l) while 4% OB and only 53% GHD with GH responses lower than 3 mg/l, the limit under which GH replacement therapy of severe de®ciency is allowed. Good intraindividual reproducibility of the GH response to GHRH arginine test was present in all groups (OB: r 0.78, P`0.0001; GHD: r 0.57, P`0.003; NS: r 0.74, P`0.0001;. CONCLUSIONS: The maximal secretory capacity of somatotrope cells is clearly less than normal in the obese but still more than is seen in GHD subjects. However, in about 50% of obese patients, the pituitary GH releasable pool overlaps with that of hypopituitaric patients with GH de®ciency. Thus, even when the maximal secretory capacity of somatotrope cells is evaluated by a potent and reproducible provocative tests such as GHRH arginine, overweight has to be taken in a great account as the cause of severely impaired GH response in patients with suspected GH de®ciency.
Introduction
It is well known that GH secretion is reduced in obesity, in which a clear cut reduction of both spontaneous and stimulated GH release has been demonstrated. 1±5 Interestingly, GH insuf®ciency in obesity is acquired and normal somatotrope function is restored by weight loss. 2, 6, 7 The pathogenesis of GH insuf®ciency in obesity is still unclear. Hypothalamic somatostatinergic hyperactivity and/or GHRH hypoactivity has been hypothesized 3 ,8±11 though a pituitary impairment due to metabolic alterations can not be ruled out. 12±18 In fact, hyperinsulinism and elevated free fatty acid levels connote obesity 19, 20 and these alterations may play a major role in impairing somatotrope function. 14,17,18,21±24 The extent of GH insuf®ciency in obesity is not clari®ed and a comparison between the impairment of somatotrope secretion in obese and in hypopituitaric patients with organic GH de®ciency has never been done.
On the other hand, the diagnosis of GH de®ciency in adulthood is still an open problem. 25, 26 In fact, in this latter condition IGF-I and IGFBP-3 assays as well as the study of spontaneous GH secretion are not reliable diagnostic tools 25±27 while insulin-induced hypoglycemia has been proposed as the golden standard test. 26 More recently, testing with GHRH combined with arginine, which likely acts via inhibition of hypothalamic somatostatin release and potentiates the GH response to the neurohormone, 28, 29 has been proposed as the best way to explore the maximal secretory capacity of somatotrope cells and to distinguish between normal subjects and GH de®cient patients. 30 At present, there is consensus about the fact that rhGH replacement therapy is allowed only for GHD patients presenting with GH peak response lower than 3 mg/l after provocative stimulation.
Based on the foregoing, the aim of the present study was to verify the extent of GH insuf®ciency in obesity evaluating the maximal secretory capacity of somatotrope by testing with GHRH arginine; the results in obese patients were compared with those in patients with organic GH de®ciency and in normal controls. To strengthen the reliability of the results, the reproducibility of the GH response to GHRH arginine was also studied in all groups. 2 ) were studied. In GHD 41 out of 49 patients had multiple anterior pituitary de®ciency and were under appropriate replacement therapy (L±thyroxine, cortisone, testosterone or oestradiol, medroxyprogesterone). The remaining 8 GHD had isolated GH de®ciency demonstrated by classical stimuli (namely, demonstrated in childhood and con®rmed in adulthood) and the anterior pituitary function other than GH secretion was normal. In OB, normal anterior pituitary function other than somatotrope secretion, had been shown by normal serum TSH and thyroid hormone, 24 h urinary cortisol and serum gonadal steroid levels. Normal menstrual bleeding or normal libido and potency had been reported. The existence of other abnormalities was excluded. No patient had diabetes or was under pharmacological treatment. All subjects were eating an unrestricted diet and their body weight had remained unchanged for 2 months before the study.
Methods

Forty
After informed consent, all subjects underwent a test with GHRH (1 mg/kg as iv bolus at 0 min) arginine (ARG, arginine hydrochloride, 0.5 g/kg infused iv from 0 to 30 min).
In 14 OB, 15 GHD, and 18 NS the test was repeated in another session, at least three days apart. All tests began at 08.30 am after an overnight fasting and 30 min after an indwelling catheter had been inserted in a cubital vein kept patent by slow saline infusion. Blood samples were taken basally, at 760 and 0 min and then every 15 min from 0 to 120 min. All samples from an individual subject were analyzed together.
Serum GH levels were measured in duplicate by immunoradiometric assay (hGH±CTK, Sorin, Italy). The sensitivity of the assay was 0.1 mg/l. The interand intra±assay coef®cients of variation were 4.9± 6.5% and 1.5±2.9% respectively. Plasma IGF±I levels were measured in duplicate by radioimmuno assay (Nichols Institute Diagnostics, San Juan, Capistrano, USA). To avoid interference by binding proteins, all samples were treated with acid ethanol. The sensitivity of the assay was 0.1 mg/l. The inter-and intraassay coef®cients of variation were 10.1±15.7% and 7.6±15.5%, respectively.
The secretory responses are expressed as absolute values (mg/l). Results are expressed as mean AE s.e.m. and individual, absolute levels. Statistical analysis of the data was carried out using non parametric Kruskal±Wallis or Wilcoxon test.
Results
Basal GH levels in OB and GHD were similar (1.1 AE 0.3 vs 0.4 AE 0.1 mg/l) and lower (P`0.0005) than those in NS (2.3 AE 1.7 mg/l).
IGF±I levels in OB (132.4 AE 8.4 mg/l) were higher (P`0.005) than those in GHD (61.6 AE 6.0 mg/l) and lower (P`0.005) than those in NS (174 AE 5.7 mg/l). IGF±I levels showed a weak negative relationship with BMI in OB (r 70.51, P`0.0001), but not in GHD and NS.
In NS, the mean peak GH response to ARG GHRH was 64.5 AE 5.4 mg/l. On the other hand, the GH responses to this test in GHD are almost absent (3.1 AE 0.4 mg/l, P`0.005 vs NS) (Figure 1 ).
In OB, the GH response to ARG GHRH test (18.4 AE 2.2 mg/l, P`0.00005) than that in NS and higher (P`0.005) than that in GHD (Figure 1) . The GH response to ARG GHRH was not related to sex or BMI in any of the groups while in OB it did not depend on regional fat distribution
The reproducibility of the GH response to ARG GHRH test was good in all groups both between subjects (GH peak: 1 vs 2 session in NS 70.4 AE 10.1 vs 76.2 AE 10.7 mg/l; GHD: 2.3 AE 0.5 vs 2.2 AE 0.6 mg/l; OB: 21.3 AE 5.7 vs 21.2 AE 4.9 mg/l) and within±subjects (r 0.74, P`0.0001; r 0.57, P`0.003 and r 0.78, P`0.001, respectively) (Figures 2 and 3) .
Analyzing the individual GH peak responses to ARG GHRH in the different groups of patients and assuming 16.5 mg/l as the minimum normal GH peak (3rd percentile of the GH response in normal subjects), as expected, all GHD (100%) had GH peaks lower than this limit, according to their GH de®ciency (Figure 4) . The peak GH response to ARG GHRH was frequently lower than the normal limit in OB (27/ 45, 60%), thus indicating their somatotrope insuf®-ciency (Fig. 4) .
Assuming a value lower than 3 mg/l as the limit indicating severe somatotrope impairment, this was present in only 26 out of 49 (53%) GHD. Even 2 OB (4%) showed GH peak lower than this limit (Figure 4 ).
Discussion
The results of the present study demonstrate that the maximal secretory capacity of somatotrope cells is clearly less than normal in obesity but still more than is seen in organic GH de®ciency. However, in about 50% of obese patients, the pituitary GH releasable pool overlaps with that of hypopituitaric patients with GH de®ciency. Noteworthy, the GH response to GHRH arginine test shows good intra-individual reproducibility, both in obese and GHD patients, as well as in normal subjects.
It is widely accepted that in obesity there is a clear reduction of both spontaneous and stimulated GH secretion 1±5,11,32 while IGF-I levels have been found high, normal or low. 15 ,33±37 Our present data con®rm that somatotrope function is reduced in this condition and, as IGF-I levels were found low as well, indicate that a true reduction in the activity of GH/IGF-I axis is present. The fact that IGF-I levels in obese patients were still higher than those in GHD may be due to the hyperinsulinism that connotes obesity 20 and it is known to positively in¯uence IGF-I synthesis. 37 The pathogenesis of GH insuf®ciency in obesity is still unclear. A hypothalamic pathogenesis for reduced somatotrope activity in obese patients has been proposed A somatostatinergic hyperactivity has been suggested by some authors 10 but it is not supported by other data. 3, 5, 34 Also our present data showing that GHRH combined with a substance likely acting via inhibition of hypothalamic somatostatin, such as arginine, 28, 29 fails to elicit a normal GH response in obesity, agree with other data 38 against the existence of an exaggerated somatostatinergic activity.
On the other hand, also the existence of GHRH hypoactivity has been proposed in obesity; 8, 39, 40 this, in turn, could cause reduced GH synthesis and, thus, explain the reduction in the maximal secretory capacity of somatotrope cells and present data. 8, 41 Other data, however, do not support the existence Figure 1 Mean ( s.e.m.) peak and area under curve (AUC) GH responses to ARG GHRH in normal subjects, obese subjects and patients with organic GH de®ciency. Figure 2 Between-subject variability in the GH response to ARG GHRH in normal subjects, patients with organic GH de®ciency and obese patients.
GH reserve in obesity M Maccario et al of impaired GHRH activity 5 while there is evidence indicating that hyperinsulinism and/or elevated free fatty acid levels, which are usually elevated in obesity 15, 19, 20 could play a major role in causing hyposomatotropinism acting via the hypothalamus or, more likely, at the pituitary level. 12, 13, 17, 18, 21, 23, 40 Con®rm-ing the metabolic pathogenesis of GH de®ciency in obesity there is the well known evidence that spontaneous and stimulated GH secretion are restored by weight loss 2, 6 and that a clear inverse relationship exists between GH secretion and body mass. 2 From a diagnostic point of view, it has to be considered that the diagnosis of GH de®ciency in adulthood is still a matter of debate though there is clear evidence for usefulness of rhGH replacement. 25 The assay of IGF-I and IGFBP-3 as well as the evaluation of spontaneous GH secretion have been found unreliable to distinguish between normal subjects and GHD patients. 25, 30 Insulin-induced hypoglycemia has been indicated as the golden standard test by some authors 25 but not by others. 29, 42, 43 On the other hand, testing with GHRH arginine, which strongly potentiates the GH-releasing effect of the neurohormone allowing for the evaluation of the maximal secretory capacity of somatotrope cells, 29 has been found reliable in distinguishing between normal and GHD subjects. 30 The results of the present study con®rm that GHRH arginine is a potent stimulatory test of the maximal secretory capacity of somatotrope cells and, noteworthy, demonstrate that it has good intraindividual reproducibility thus strengthening its reliability. The minimum normal limit of GH peak response to this test (16.5 mg/l) is higher than those arbitrarily assigned for other provocative stimuli and allows to clearly show that patients with organic GHD have subnormal GH response distinguishing them from normal subjects. Interestingly, assuming a GH peak response lower than 3 mg/l, as evidence for severe somatotrope impairment which needs rhGH replacement therapy, 31 only 60% of GHD patients were below this limit. This evidence implies that in a large percentage of adult patients with GHD, the impairment of somatotrope function is partial and does not need replacement therapy. 44 Noteworthy, in agreement with other studies with classical provocative stimuli, 1,3±5 even when the maximal secretory capacity of somatotrope cells is evaluated by a potent and reproducible provocative test such as GHRH arginine, overweight has to be taken in a great account as the cause of severely impaired GH response in patients with suspected GH de®-ciency. In fact, our study demonstrates that the reduction of the GH reserve in obesity may be so marked that 50% of obese patients with otherwise normal pituitary function may have such an important impairment of the GH response to GHRH arginine that it overlaps with that seen in hypopituitaric patients with GH de®ciency.
Thus, there is an overlap between the maximal secretory capacity of somatotrope cells in hypopituitaric and obese patients which are organic and functional models of GH de®ciency, respectively. Of course, we are not proposing obese patients for either routinary assessment of the GH reserve and/or MR scans of the hypothalamic-pituitary area or for Figure 3 Within-subject variability in the GH response to ARG GHRH in normal subjects, patients with organic GH de®ciency and obese patients. Figure 4 Individual GH peaks after ARG GHRH in obese patients (OB) and in patients with organic GH de®ciency (GHD). Dotted line at 16.5 mg/l indicates lowest normal peak GH response. 30 Dotted line at 3.0 mg/l indicates the peak GH response under which severe GHD is shown and rhGH replacement is allowed. 31 treatment with rhGH. In fact, there is evidence showing that GH secretion in obesity is restored by weight loss. 2, 6 Moreover, clinical data and IGF-I levels are able to distinguish between obesity and hypopituitarism. 45 In all, our present data show that the pituitary GH releasable pool in obesity is impaired to an extent frequently overlapping with that in organic GH de®-ciency. This evidence further points to take into great account the adiposity before concluding that an hypopituitaric patient is GH de®cient.
